Latest Breaking News On - Caroline baumal - Page 3 : comparemela.com

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Q4 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.

United statesRaymond jamesTim sullivanTazeen ahmadColleen kusySalveen richterCedric francoisJon millerYigal nochomovitzMadam townsendAnupam ramaPhil nadeauSteve seedhouseCaroline baumalYigal natromovitzMeredith kaya

Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $60 00 at Wedbush

Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $60 00 at Wedbush
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Pascal deschateletsCaroline baumalRaymond jamesNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticals stockCim investment management incNeuberger berman groupJpmorgan chase coFirst horizon advisors incSecurities exchange commissionAnalyst recommendations for apellis pharmaceuticalsApellis pharmaceuticals incInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals company profileAdvisor group holdings incApellis pharmaceuticals

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives Average Rating of Moderate Buy from Brokerages

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives Average Rating of Moderate Buy from Brokerages
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Raymond jamesAlec machielsCaroline baumalInsider transactions at apellis pharmaceuticalsApellis pharmaceuticals company profileApellis pharmaceuticalsStephens consultingApellis pharmaceuticals incNational bankInstitutional trading of apellis pharmaceuticalsNeedham companyCovestor ltdApellis pharmaceuticals price performanceFirst horizon advisors incWells fargo companyWealth management inc

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Shares Purchased by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 64.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 27,396 shares of the company’s stock after buying an additional 10,713 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Apellis Pharmaceuticals were worth $1,042,000 at the […]

Caroline baumalCedric francoisApellis pharmaceuticals incNorges bankQuarter for apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyJennison associatesOrion portfolio solutionsSecurities exchange commissionApellis pharmaceuticals stock downGoldman sachs groupNeedham companyVanguard group incApellis pharmaceuticalsPricet rowe associates incApellis pharmaceuticals profile

Apellis Pharmaceuticals Inc Chief Medical Officer Caroline Baumal Sells 2,751 Shares

On January 4, 2024, Chief Medical Officer Caroline Baumal executed a sale of 2,751 shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS).

Apellis pharmaceuticals incPossible value trapThink twiceChief medical officerIopharmaceutical companyCaroline baumalNsider transactions